Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 293 participants.
Also called NCT01582230
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 293 participants
- Sponsor
- Registry
-
NCT01582230
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China, Philippines, Singapore, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT01582230. Randomized; double masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2013-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Vildagliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01582230- Content hash
f4bef4052d38eae84f6a803a07f20204b859de6176dd0bb7f64a89d2d694cb44